Her-2 Homodimer Detection for Cancer Treatment Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a reliable way to determine whether a subject with Her-2 positive cancer will respond to treatment with Her2-acting agents like trastuzumab or chemotherapeutic agents, leading to ineffective treatment and potential toxicity.
Innovation Solution
A method involving the detection of Her-2 and Her-2 homodimers in biological samples using assays like eTag™, which predicts responsiveness and time course of disease by comparing sample amounts to predetermined cutoffs, allowing for personalized treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional IHC or FISH analysis is used to detect Her-2 overexpression, then Her-2 positive patients can be identified, but treatment response prediction remains unreliable with only 20-35% objective response rates
Solution Approach 1:
The patent segments the Her-2 detection into multiple distinct biomarkers: total Her-2 expression levels and Her-2 homodimer levels. This segmentation allows for more granular prediction of treatment response, moving beyond the single binary classification of conventional IHC or FISH analysis.
Solution Approach 2:
The patent introduces a new parameter (Her-2 homodimer level) in addition to the conventional Her-2 expression level. By measuring and comparing multiple parameters (total Her-2, homodimer Her-2, and their ratio), the diagnostic method achieves more accurate treatment response prediction.
2Adaptability or versatility
If Her2-acting agents like trastuzumab are administered to all Her-2 positive patients, then treatment coverage is maximized, but costly treatment is provided to patients unlikely to respond
Solution Approach 1:
The patent performs preliminary diagnostic assessment using the dual-parameter method (total Her-2 and homodimer levels) before initiating treatment. This preliminary action identifies patients with high likelihood of response, allowing clinicians to prescribe trastuzumab confidently and avoid costly treatment in patients unlikely to benefit.
Solution Approach 2:
The patent provides feedback through the Her-2 homodimer to total Her-2 ratio, which indicates treatment responsiveness. This feedback mechanism enables clinicians to make informed decisions about treatment allocation, directing resources to patients most likely to respond.
3Reliability
If combination therapy with trastuzumab plus chemotherapy is administered, then treatment efficacy is improved for some patients, but toxic effects increase for patients unlikely to respond
Solution Approach 1:
The patent performs preliminary risk stratification using the Her-2 homodimer ratio before initiating combination therapy. Patients with low homodimer ratios are identified as likely responders and can safely receive combination therapy, while patients with high ratios are identified as unlikely responders and can avoid the toxicities of chemotherapy.
Solution Approach 2:
The patent applies different treatment recommendations based on local characteristics of the tumor's Her-2 status. Rather than a uniform approach, the treatment strategy is customized according to the specific homodimer ratio profile, optimizing efficacy while minimizing toxicity for each patient subgroup.
4Ease of operation
If no predictive biomarker method is used, then all Her-2 positive patients receive standard treatment, but treatment personalization and optimization are lost
Solution Approach 1:
The patent creates a universal diagnostic method that can be applied to all Her-2 positive breast cancer patients. The method simultaneously provides multiple pieces of information (total Her-2 level, homodimer level, and their ratio) that serve different predictive functions, making it a multi-functional diagnostic tool.
Solution Approach 2:
The patent adds the Her-2 homodimer parameter to the conventional diagnostic framework. This additional parameter transforms the simple binary classification into a more nuanced multi-parameter system that maintains ease of use while dramatically improving predictive precision.
Data Source
AI summary
In certain aspects, the present invention provides methods for determining whether a Her-2 positive cancer is likely to respond to treatment with a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a slow disease progression. In other aspects, the present invention is drawn to methods for determining whether a subject with a Her-2 positive cancer is unlikely to respond to treatment with at least one chemotherapeutic agent in addition to a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a fast disease progression.